18
Oct
2018
AbbVie Plunks Down $100M Upfront for Morphic’s Oral Integrin Inhibitors for Fibrosis
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
17
Oct
2018
Making it Easy to Share Biological Data: John Wilbanks on The Long Run Podcast
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
12
Oct
2018
Allogene’s Megabucks IPO, CVS-Aetna Muscling Through, & Consumer Genetics in the Mainstream
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
11
Oct
2018
The MIT Biotech Group Alumni: Where Are They Now?
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
5
Oct
2018
Nobel Highlights and Lowlights, MSK Fallout Continues, Pfizer CEO Stepping Down
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
3
Oct
2018
Overcoming a Bad Job Market, Finding a Path in Biotech: Sabah Oney on The Long Run
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
28
Sep
2018
Roche’s PD-L1 ‘Practice-Changer,’ J&J Dumps Geron, and Amarin’s Fish-Oil Surprise
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
21
Sep
2018
WuXi Eyes A Fresh $1B, California Aims at AbbVie, and MSK’s Industry Ties in the Spotlight
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
19
Sep
2018
Health Data That Can Meet Pharma Standards: Amy Abernethy on The Long Run
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
14
Sep
2018
Baselga Brouhaha, a Shkreli Imitator, and Autoimmunity Strides from BMS and Gilead
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
5
Sep
2018
Telling Biotech Stories on TV: Listen to Meg Tirrell on The Long Run Podcast
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
5
Sep
2018
Fulcrum Gets $80M to Test Small Molecules Against Rare Disorders of Gene Expression
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
24
Aug
2018
Exact Goes from Madison Wis. to Madison Ave. & IPO Candidates Get in Line
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
22
Aug
2018
Building Startups With Pharma Needs in Mind: Thong Le on The Long Run Podcast
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
17
Aug
2018
Alnylam Crosses the Threshold, Gilead’s Changing of the Guard & Gene Therapy Financings Galore
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
8
Aug
2018
The Antibiotic Opportunity? Spero’s Ankit Mahadevia on The Long Run Podcast
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
7
Aug
2018
5AM, NEA Lead $50M Bet on Akouos, Crafting Gene Therapy for the Ear
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
3
Aug
2018
BeiGene’s Cash Haul, Illumina’s Big Q2, & Startups Keep Hiring Pharma Vets
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
31
Jul
2018
Verana, Backed by GV & Brook Byers, Grabs $30M to Squeeze Meaning Out of EMRs
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
27
Jul
2018
An Alzheimer’s Hope-Fest, GSK Cozies Up to 23andMe, & A Gilead Legend Steps Aside
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.